Alnylam Pharmace. buy Oppenheimer Holdings Inc.
Start price
04.08.25
/
50%
€359.70
Target price
04.08.26
€423.31
Performance (%)
-5.87%
Price
12.12.25
€338.60
Summary
This prediction is currently active. With a performance of -5.87%, the BUY prediction for Alnylam Pharmace. by Oppenheimer_Holdings is down slightly. This prediction currently runs until 04.08.26. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -13.930% | -13.930% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating. They now have a $490.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat